Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cassiopea SpA    SKIN   IT0005108359

CASSIOPEA SPA

(SKIN)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/07/2019 06/11/2019 06/12/2019 06/13/2019 06/14/2019 Date
43.5(c) 42.5(c) 42.7(c) 42.7(c) 42.7(c) Last
380 2 392 1 767 2 096 794 Volume
+1.87% -2.30% +0.47% 0.00% 0.00% Change
More quotes
Financials (EUR)
Sales 2019 -
EBIT 2019 -18,5 M
Net income 2019 -21,2 M
Debt 2019 18,3 M
Yield 2019 -
Sales 2020 60,1 M
EBIT 2020 -6,93 M
Net income 2020 -16,7 M
Debt 2020 16,8 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 0
EV / Sales2020 6,75x
Capitalization 389 M
More Financials
Company
Cassiopea SpA is an Italy-based company engaged in the biotechnology and medical research industry. The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. The Company's current focus is... 
More about the company
Latest news on CASSIOPEA SPA
05/08COSMO PHARMACEUTICALS : FDA Allowance of IND application for CB-03-10
AQ
04/16Cassiopea Announces Very Positive Phase II Twelve Months Results for Breezula..
TE
04/01Cosmo Full-Year Report 2018
AQ
03/26Cassiopea Announces Positive Results from Phase III Acne Open-Label Safety St..
TE
03/19Cassiopea announces results of ordinary and extraordinary shareholders meetin..
TE
02/08Cassiopea announces 2018 Results in line with expectations
TE
2018Cassiopea announces attainment of all primary and secondary endpoints and hig..
TE
2018Cassiopea enters into loan agreement with Cosmo Pharmaceuticals NV
TE
2018CASSIOPEA : Command and control system
AQ
2018Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for C..
TE
More news
Analyst Recommendations on CASSIOPEA SPA
More recommendations
Sector news : Bio Therapeutic Drugs
06/14REGENERON PHARMACEUTICALS : Says Early-Stage Results Positive for REGN1979 in Ly..
DJ
06/13GSK signs up gene-editing pioneers in drug discovery alliance
RE
06/11GENMAB : J&J's Janssen in Pact for HexaBody-CD38 License
DJ
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
More sector news : Bio Therapeutic Drugs
Chart CASSIOPEA SPA
Duration : Period :
Cassiopea SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSIOPEA SPA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 70,0 €
Spread / Average Target 80%
EPS Revisions
Managers
NameTitle
Diana Harbort Chief Executive Officer & Executive Director
Jan Egbert de Vries Non-Executive Chairman
Marco Pasero Chief Operating Officer
Hans Christoph Tanner CFO, Head-Investor & Media Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CASSIOPEA SPA16.67%434
GILEAD SCIENCES6.09%80 909
VERTEX PHARMACEUTICALS2.72%42 680
REGENERON PHARMACEUTICALS-18.28%32 744
GENMAB10.45%10 857
SAREPTA THERAPEUTICS INC9.57%8 523